Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas




descargar 0.53 Mb.
títuloInmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas
página10/10
fecha de publicación20.01.2016
tamaño0.53 Mb.
tipoDocumentos
b.se-todo.com > Documentos > Documentos
1   2   3   4   5   6   7   8   9   10

161. Canonica GW, Bousquet J, Casale T. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009 Dec;64 Suppl 91:1-59.





162. Haycox A, Drummond M, Walley T. Pharmacoeconomics: integrating economic evaluation into clinical trials. Br J Clin Pharmacol 1997;43:559-62.


163. Alergológica 2005. Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España en 2005. Ed. Luzán 5 S.A. Madrid 2006.


164. European Allergy White Paper – Allergic diseases as a public health problem in Europe. The UCB Institute of Allergy, 1997.


165. Nieto A, Álvarez –Cuesta E, Boquete M, Mazón A, De la Torre F. The cost of asthma Treatment in Spain and rationalizing the expense. J Invest Allergol Clin Immunol 2001;11(3): 139-148.


166. Vollmer WM, O‘Hollaren M, Ettinger KM, Stibolt T, Wilkins J, et al. Speciality differences in the management of asthma. Arch Intern Med 1997;157:1201-8.


167. Hernández García J. Carta al director. Rev. Esp. Alergol. Inmunol. Clin. 1995. 10:45.


168. Negro Álvarez JM, García Cánovas A, Funes Vera E. Rentabilidad terapéutica de la inmunoterapia en el asma IgE dependiente. Act Ped Esp 1997, 55:61-6.


169. Bernstein JA. Pharmacoeconomic considerations for allergen immunotherapy. Clin Allergy Immunol 2004;18:151-64


170. Kumar P, Kamboj S, Rao P, Cai X, Vedere T, Gupta S. The cost of care and quality of life in patients with allergic rhinitis on allergen immunoterapy. ACI international 1997; 9:133-5.


171. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis.Ann Allergy Asthma Immunol 1999;82:339-47.


172. Boquete M, Carballada F, Expósito F, González A. Preventive immunotherapy. Allergol Immunopathol 2000;28(3):89-93.


173. Schadlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000;17(1):37-52.


174. Bousquet J, Scheinmann P, Neukirch F, Omnes LF, Jasso-Mosqueda et al. Pharmaco-economic assessment of specific immunotherapy in the treatment of allergic rhinitis and asthma: Relevance of a modelling approach.Abstract Book XXIII EAACI Congress. 12-16 June 2004, Amsterdam. Pag.135.


175. Omnes LF, Bousquet J, Scheinmann P, Neukirch F, Jasso-Mosqueda G, Chicoye A, Champion L, Fadel R. Pharmacoeconomic assessment of specific immunotherapy versus current symptomatic treatment for allergic rhinitis and asthma in France. Allerg Immunol (Paris). 2007 May;39(5):148-56.


176. Durham S, Walker S, Varga EM, Jacobson M, O‘Brien F, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468-475.


177. Petersen KD, Gyrd-Hansen D, Dahl R. Health-Economic Analyses of subcutaneous Specific Immunotherapy for grass pollen and mite allergy. Allergol et Immunopathol 2005;33(6):296-302


178. Sullivam TJ, Selner JC, Patterson R, et al. Expert care and immunotherapy for asthma. Am Coll Allergy Asthma Immunol 1996; 1-25.


179. Keiding H, Jorgensen KP. A cost-effectiveness analysis of immunotherapy with SQ allergen extract for patients with seasonal allergic rhinoconjunctivitis in selected European countries. Current Med Research Op 2007;23(5):1113-20.


180. Mauro M, Russello M, Alesina R, Sillano V, Alessandrini A, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Europ Ann Allergy Clin Immunol 2006;38(1):31-34.


181. Berto P, Passalacqua G, Crimi N, Frati F, Ortolani C, Senna G, Canonica GW, Italian SAPAI Study Group. Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Ann Allergy Asthma Immunol. 2006 Nov;97(5):615-21.


182. Berto P, Bassi M, Incorvaia C, Frati F, Puccinelli P, Giaquinto C, Cantarutti L, Ortolani C. Cost effectiveness of sublingual immunotherapy in children with allergic rhinitis and asthma. Allerg Immunol (Paris). 2005 Oct;37(8):303-8.


183. Blanco Guerra C, García Dumpiérrez A, Almeida Quintana L. Utilidad y limitaciones de las técnicas diagnósticas. En: Blanco C, Quirce S, eds. Alergia al látex. Barcelona: MRA Ediciones; 2002; 101-19.


184. Tabar AI, Gómez B, Arroabarren E, Rodríguez M, Lázaro I, Anda M. Perspectivas de tratamiento de la alergia al látex: inmunoterapia. An. Sis. Sanit. Navar 2003; 26(2): 97-102


185. Sastre Domínguez J. Inmunoterapia con látex. En: Blanco C, Quirce S, eds. Alergia al látex. Barcelona: MRA Ediciones; 2002; 247-52.


186. Toci G, Shah S, Al-Faquih A, Beezhold D, Mc Geady SJ. Oral latex desensitization of healthcare workers. J Allergy Clin Immunol 1998; 101: S665.


187. Pereira C, Rico P, Lourenco M, Lombardero M, Pinto-Mendes J, Chieira C. Specific immunotherapy for occupational latex allergy. Allergy 1999; 54: 291-3.


188. Nucera E, Schiavino D, Buonomo A, Roncallo C, del Ninno M, Milani A, Pollastrini E, Patriarca G. Latex rush desensitization. Allergy 2001; 56: 86-7.


189. Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106(3): 585-90.


190. Tabar A, Anda M, Bonifazi F, Bilo MB, Leynadier F, Fuchs T, Ring J, Galvain S, Andre C. Specific immunotherapy with standardized latex extract versus placebo in latex-allergic patients. Int Arch Allergy Immunol 2006; 141: 369-76.


191. Sastre J, Fernández-Nieto M, Rico P, Martín S, Barber D, Cuesta J, de las Heras M, Quince S. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111(5): 985-94.


192. Nettis E, Colanardi MC, Soccio AL, Marcandrea M, Pinto L, Ferrannini A, Cursi A, Vacca A. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. British Journal of Dermatology 2007; 156: 674-81.


193. Bernardini R, Campodonico P, Burastero S, Azzari C, Novembre E, Pucci N, Massai C, de Martino M, Vierucci A. Sublingual immunotherapy with a latex extract in pediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006; 22(8): 1515-22.


194. B. Lauren Charous, Carlos Blanco, Susan Tarlo, Robert G. Hamilton, Xaver Baur, Donald Beezhold, Gordon Sussman and John W. Yunginger. Natural rubber latex allergy after 12 years: Recommendations and perspectives. J. Allergy Clin. Immunol. 2002; 109: 31-34.


195. San Miguel Mocin MM, García Figueroa B, Sanz Larruga ML, Lasa Luaces EM. Concepto, epidemiología y fisiopatología de la alergia a los alimentos. En: Peláez Hernández A, Dávila González IJ, eds. Tratado de alergología. Madrid 2007; pg. 791-3.


196. Casimir G, Cuvelier P, Allard S, Duchateau J. Life-threatening fish allergy successfully treated with immunotherapy. Pediatr Allergy Immunol 1997; 8(2): 103-5


197. Swaminathan S, Heddle RJ. Wheat flour immunotherapy in baker’s asthma. Intern Med J 2007; 37(9): 663-4.


198. Mempel M Rakoski J, Ring J, Ollert M. Severe anaphylaxis to kiwi fruit: immunologic changes related to successful sublingual allergen immunotherapy. J Allergy Clin Immunol 2003; 111(6): 1406-9.


199. Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. Hepatogastroenterology 1998; 45(19): 52-8.


200. Martorell Aragonés A, Félix Toledo R, Cerdá Mir JC, Marorell Calatayud A. Oral rush desensitization to cow milk. Following of desensitized patients during three years. Allergol et Immunopathol 2007; 35(5): 174-6.


201. Ruëff F, Eberlein-König B, Przybilla B. Oral hyposensitization with celery juice. Allergy 2001; 56: 82-3.


202. Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol 2008;121:1344-50


203. Didier A, Malling H_J, Worm M, Horak F; Jäger S, Montagut A et al. Optimal dose, Efficacy and safety of Once-Daily Sublingual Immunotherapy with a 5-Grass Pollen Tablet for Seasonal Allergic Rhinitis. J Allergy Clin Immunol 2007; 120: 1338-45


204. Whan U; Tabar AI, Halken S, Montagut A, Legall M. Efficacy and Safety of five-grass-polen Sublingual Immunotherapy Tablets in Paediatric Allergic Rhinoconjuntivitis. J Allergy Clin Immunol 2009 123(1):160-166


205. Tupker RA, de Monchy JG, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996;97:1064-70.


206. Bussmann C, Böckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol. 2006 Dec;118(6):1292-8. Epub 2006 Oct 18.


207. GB Pajno, L Caminiti, D Vita , G Barberio, G Salzano, F Lombardo, GW Canonica, G Passalacqua. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study J Allergy Clin Immunol. 2007;120:164-70.


208. Nomenclature and structural bology of allergens. J Allergy Clin Immunol. 2007;119:414-20


209. Chapman MD, Smith AM, Vailes LD, Pomés A. Recombinant allergens for immunotherapy. Allergy Asthma Proc. 2002 Jan-Feb;23(1):5-8


210. Valenta R, Niederberger V Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007 Apr; 119 (4):826-30. Epub 2007 Mar 1.


211. Wild C, Wallner M, Hufnagl K, Fuchs H, Hoffmann-Sommergruber K, Breiteneder H, Scheiner O, Ferreira F, Wiedermann U. A recombinant allergen chimer as novel mucosal vaccine candidate for prevention of multi-sensitivities. Allergy. 2007 Jan;62(1):33-4


212. Larche M Update on teh current status of peptide immunotherapy..J Allergy Clin Immunol. 2007;119: 906-9.


213. Kussebi et al. A major allergen gene-fusion proteína for potencial usage in allergen-specific immunotherapy. J Allergy Clin Immunol. 2005;115: 323-9.

1   2   3   4   5   6   7   8   9   10

similar:

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconLas técnicas de manipulación del adn están en estado incipiente,...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconDel griego klima, clima y therapeia, tratamiento. Aplicación, a la...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconResumen el tratamiento de la Pseudoartrosis Congénita de Tibia y...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconPlegamiento y agregación errónea de las proteínas y su relación con las enfermedades

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconLas enfermedades crónicas adquieren el carácter de “enfermedad social”...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEs del último grupo de enfermedades genéticas. Estas enfermedades...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEnfermedades en Ciudad Juárez, México y el mundo y programas gubernamentales...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconReacciones alérgicas fatales

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconEl mayor problema a través de la historia de la humanidad, con relación...

Inmunoterapia con alérgenos en el tratamiento de las enfermedades alérgicas iconResumen Las enfermedades ampollosas autoinmunes (eaa) comprenden...




Todos los derechos reservados. Copyright © 2019
contactos
b.se-todo.com